Experienced in Nephrectomy

Dr. Jean H. Hoffman-Censits

Oncology | Hematology Oncology
Johns Hopkins University
600 N Wolfe St, Blalock 266, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Experienced in Nephrectomy
Johns Hopkins University
600 N Wolfe St, Blalock 266, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jean Hoffman-Censits is an Oncologist and a Hematologist Oncology provider in Baltimore, Maryland. Dr. Hoffman-Censits is rated as an Experienced provider by MediFind in Nephrectomy. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Endoscopy. Dr. Hoffman-Censits is currently accepting new patients.

Her clinical research consists of co-authoring 102 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles and participated in 1 clinical trial in the study of Nephrectomy.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolfe St, Blalock 266, Baltimore, MD 21287
Other Locations
JOHNS HOPKINS UNIVERSITY
5255 Loughboro Rd Nw, Sibley Memorial Hospital, Washington, DC 20016
JOHNS HOPKINS UNIVERSITY
8600 Old Georgetown Rd, Bethesda, MD 20814
JOHNS HOPKINS UNIVERSITY
601 N Caroline St, Baltimore, MD 21287
JOHNS HOPKINS UNIVERSITY
5755 Cedar Ln, Columbia, MD 21044
JOHNS HOPKINS UNIVERSITY
5759 Cedar Ln, Columbia, MD 21044

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Radiation, Other, Procedure
Study Phase: Phase 1
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2024
Intervention Type: Drug, Radiation
Study Drugs: Enzalutamide, Goserelin Acetate, Leuprolide Acetate
Study Phase: Phase 1
Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Drug
Study Phase: Phase 2
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Enrollment Status: Completed
Publish Date: May 13, 2024
Intervention Type: Procedure, Other, Drug
Study Drugs: Enzalutamide, Ribociclib
Study Phase: Phase 1/Phase 2
Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 10, 2023
Intervention Type: Procedure, Drug
Study Drugs: Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine, Carboplatin, Pegfilgrastim
Study Phase: Phase 2
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: October 04, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 26, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

102 Total Publications

Clinicopathologic and Prognostic Features of Sarcomatoid Urothelial Carcinoma: A Retrospective Study of 136 Patients With Emphasis on Early-Stage (pT1) Disease.
Clinicopathologic and Prognostic Features of Sarcomatoid Urothelial Carcinoma: A Retrospective Study of 136 Patients With Emphasis on Early-Stage (pT1) Disease.
Journal: The American journal of surgical pathology
Published: September 15, 2025
Similar Doctors
Advanced in Nephrectomy
Dr. Michael A. Carducci
Oncology
Advanced in Nephrectomy
Dr. Michael A. Carducci
Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (0.1 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Carducci is an Oncologist in Baltimore, Maryland. Dr. Carducci is rated as an Elite provider by MediFind in Nephrectomy. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Advanced in Nephrectomy
Dr. Yasser A. Ged
Oncology
Advanced in Nephrectomy
Dr. Yasser A. Ged
Oncology

Johns Hopkins University

5759 Cedar Ln, 
Columbia, MD 
 (16.7 miles away)
443-718-3738
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Yasser Ged is an Oncologist in Columbia, Maryland. Dr. Ged is rated as a Distinguished provider by MediFind in Nephrectomy. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Wilms Tumor, Nephrectomy, and Thrombectomy. Dr. Ged is currently accepting new patients.

Experienced in Nephrectomy
Dr. Noah M. Hahn
Hematology Oncology | Oncology | Hematology
Experienced in Nephrectomy
Dr. Noah M. Hahn
Hematology Oncology | Oncology | Hematology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (0.1 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noah Hahn is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Hahn is rated as an Elite provider by MediFind in Nephrectomy. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy. Dr. Hahn is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoffman-Censits's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile